Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial - Jambor, I; Kuisma, A; Ramadan, S (Acta oncologica (Stockholm, Sweden), 2016)
et al.